Candel Therapeutics launches phase 3 lung cancer trial for CAN-2409

June 30, 2026 8:05 AM

Candel Therapeutics, Inc. (Nasdaq: CADL) has initiated a global pivotal phase 3 clinical trial, called AURORA, evaluating its investigational therapy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found